A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy (MEC).

A Phase II Study of NK012 in Locally Advanced Non-Resectable Metastatic Breast Cancer Patients with Triple Negative Phenotype.

A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer

Phase 2 Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer

A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624. Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS or BRAF Mutant Colorectal Adenocarcinoma that Has Progressed Following a First Line Oxaliplatin- andFluoropyrimidine-Containing Regimen.

Randomized Double-Blind, Placebo Controlled, Phase II Study of FOLFOX/ Bevacizumab with or without Met MAb as First-Line Treatment for Patients with Metastatic Colorectal Cancer

A retrospective cohort study of infusion reactions due to Vectibix (Panitumumab)

A randomized Phase 2 study evaluating the safety and efficiency of various drugs in Metastatic and Relapsed/Refractory colorectal cancer.

Randomized, Multicenter, Open-label, Active-Controlled, Phase 2 Study of LY2510924 and Sunitinib versus Sunitinib in Patients with Metastatic Renal Cell Carcinoma

An Open Label, Multi-Center IRESSA, Clinical Access Program of Gefitinib 250 mg (Iressa) for the continued treatment of patients in the United States who are currently benefiting or have benefited from Gefitinib treatment

A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer

A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Metmab In Combination With Tarceva (Erlotinib), In Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer (NSCLC), Who Have Received Standard Chemotherapy For Advanced Or Metastatic Disease.

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Treatment of Physician’s Choice in Subjects with Advanced Non-Small Cell Lung Cancer

TOPPS Phase II trial for patients with stage III/IV Non-Small Cell Lung Cancer.

Phase II study for patients with Stage IB, II and III Non-Small-Cell lung cancer.

A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine (IMGN901) in Combination with Carboplatin/Etoposide in Patients with Advanced Solid Tumors including Extensive Stage Small Cell Lung Cancer.

A Phase III, Randomized, Double-Blinded Study Comparing the combination of the BRAF Inhibitor, GSK2118436 and the MEK Inhibitor, GSK1120212 to Each Single Agent Combined with Placebo in Subjects with Advanced (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation-Positive Melanoma

Phase I/II study for patients with Sates III/IV or Relapse/Refractory ovarian cancer.

A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma.

A Registry of Sipuleucel-T Therapy in Men with Advanced Prostate Cancer.

Lexington Medical Center has launched 3 cancer-related studies based on our tissue banking program

Connect CLL Registry Protocol

A Phase I/II Study of Fludarabine, Rituximab, and Lenalidomide in Minimally Treated and Untreated Patients with Chronic Lymphocytic Leukemia

An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non- Germinal Center B-Cell like Diffuse Large B-Cell Lymphoma

A Phase III, Multicenter, Randomized Trial Comparing the Efficacy of GA101 in Combination with CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of patients with Multiple Myeloma Who are not Candidates for High Dose Chemotherapy.